Genetic screening guidelines and personalized medicine: Who should be tested

By Peter Hofland, Ph.D., OncZine

Updated genetic screening guidelines with practice recommendations for genetic and familial high-risk breast, ovarian and pancreatic cancers, published by the National Comprehensive Cancer Network (NCCN), feature emerging evidence on personalized medicine.

The new guidelines, created and maintained by an interdisciplinary panel of experts from NCCN leading cancer centers as well as patients and advocates, include several updates—including new and expanded sections on risk assessment and management related to three major cancer types and also maintaining a more conservative approach toward testing practices where the evidence is still lacking.

In the rapidly-moving field of cancer care and genetics, the updated NCCN Guidelines® combine the latest evidence and expert consensus. These recommendations are firmly supported by quality research and establish the best management paradigms that improve outcomes for people with cancer. Read more …